ArticlePharmaceutics2021

A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes.

Curtis K Johnston et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.